Antigenic targets for the immunotherapy of acute myeloid leukaemia
Khan, Ghazala; Orchard, Kim; Guinn, Barbara-ann
Dr Barbara Guinn B.Guinn@hull.ac.uk
Reader in Biomedical Sciences
One of the most promising approaches to preventing relapse is the stimulation of the body's own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high frequency with which patients achieve first remission, and the diffuse nature of the disease throughout the periphery, makes immunotherapy particularly appealing following induction and consolidation therapy, using chemotherapy, and where possible stem cell transplantation. Immunotherapy could be used to remove residual disease, including leukaemic stem cells from the farthest recesses of the body, reducing, if not eliminating, the prospect of relapse. The identification of novel antigens that exist at disease presentation and can act as targets for immunotherapy have also proved useful in helping us to gain a better understand of the biology that belies AML. It appears that there is an additional function of leukaemia associated antigens as biomarkers of disease state and survival. Here, we discuss these findings.
|Journal Article Type||Article|
|Publication Date||Jan 23, 2019|
|Journal||Journal of Clinical Medicine|
|Peer Reviewed||Peer Reviewed|
|Series Title||Special Issue Immunotherapies for Acute Myeloid Leukemia|
|APA6 Citation||Khan, G., Orchard, K., & Guinn, B. (2019). Antigenic targets for the immunotherapy of acute myeloid leukaemia. Journal of Clinical Medicine, 8(2), 134. https://doi.org/10.3390/jcm8020134|
|Keywords||Acute myeloid leukaemia; Cancer-testis antigen; Human; Clinical trial; Immunotherapy|
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
You might also like
Urine biomarkers for the early detection of ovarian cancer – are we there yet?